NeonMind Biosciences Inc (TSE:LCR)
:LCR
Want to see TSE:LCR full AI Analyst Report?
Top Page
NeonMind Biosciences Inc
(LCR)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.05
▲(12.50% Upside)
Action:Reiterated
Date:05/14/26
The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, negative cash flow, and negative equity). Technicals provide some offset with the price trading above major moving averages, but overbought RSI/Stoch readings temper that support. Valuation remains unattractive/unclear given the negative P/E and lack of dividend yield data.
Positive Factors
Focused R&D on psilocybin therapies
A clear, specialized R&D focus on psilocybin-based mental health treatments establishes a durable strategic direction. Specialization supports the development of proprietary drug candidates, targeted clinical programs and potential IP/licensing pathways, creating a repeatable route to commercial partnerships if trials succeed.
Negative Factors
No meaningful revenue
The absence of recurring revenue across multiple years means the company remains pre-commercial and dependent on external funding. Long-term sustainability hinges on successful clinical outcomes or licensing; until then, there is no proven commercial model to generate operating cash flow or validate market demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused R&D on psilocybin therapies
A clear, specialized R&D focus on psilocybin-based mental health treatments establishes a durable strategic direction. Specialization supports the development of proprietary drug candidates, targeted clinical programs and potential IP/licensing pathways, creating a repeatable route to commercial partnerships if trials succeed.
Read all positive factors
NeonMind Biosciences Inc (LCR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$3.70M
Dividend YieldN/A
Average Volume (3M)290.69K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue GrowthN/A
EPS Growth-23.79%
CountryCA
Employees28
SectorBasic Materials
Sector Strength58
IndustryIndustrial Materials
Share Statistics
EPS (TTM)-0.01
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NeonMind Biosciences Inc Business Overview & Revenue Model
Company Description
Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mex...
How the Company Makes Money
NeonMind Biosciences generates revenue primarily through research and development activities that lead to the development of patented treatments, followed by licensing or collaboration agreements with pharmaceutical companies and healthcare provid...
NeonMind Biosciences Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Jun 2025 | Jun 2024 | Mar 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -1.58M | -897.00 | ― | -1.75M | -7.83M |
| Net Income | -1.75M | -1.54M | ― | -2.03M | -7.21M |
Balance Sheet | |||||
| Total Assets | 1.09M | 91.12K | 719.33K | 129.43K | 1.34M |
| Cash, Cash Equivalents and Short-Term Investments | 206.03K | 13.98K | 135.40K | 69.91K | 967.27K |
| Total Debt | 1.14M | 1.19M | 1.04M | 846.94K | 450.01K |
| Total Liabilities | 1.74M | 2.00M | 1.33M | 1.53M | 1.05M |
| Stockholders Equity | -635.18K | -1.90M | -612.89K | -1.40M | 290.30K |
Cash Flow | |||||
| Free Cash Flow | -988.65K | -89.79K | -1.31M | -1.22M | -5.82M |
| Operating Cash Flow | -988.66K | -89.79K | -1.13M | -1.08M | -5.82M |
| Investing Cash Flow | -129.42K | 37.60K | -36.15K | 72.14K | 389.12K |
| Financing Cash Flow | 1.29M | 0.00 | 627.93K | 271.00K | 6.20M |
NeonMind Biosciences Inc Technical Analysis
Neutral
0.04
Price Trends
0.04
Positive
0.04
Negative
0.05
Negative
Market Momentum
<0.01
Negative
51.20
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LCR, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.20 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:LCR.
NeonMind Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (61)
TSE:LCR
NeonMind Biosciences Inc
0.04
0.00
0.00%
TSE:LSD.H
Lightspeed Discoveries
0.05
0.02
66.67%
TSE:LEXT
Lexston Life Sciences Corp.
0.06
-0.09
-60.71%
NeonMind Biosciences Inc Corporate Events
Business Operations and StrategyExecutive/Board Changes
Lancaster Resources Refreshes Board as It Sharpens Exploration Focus
Positive
Mar 5, 2026
Lancaster Resources Inc. has announced that director Penny White resigned from the board on March 3, 2026, with the company expressing appreciation for her contributions. At the same time, the miner appointed geologist Rob Heaslop to its board of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.